Rituximab in steroid-refractory immune-related pancreatitis: a case report.
| Autor: | Santoro A; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy., Masini S; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy., Cavina R; IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy., Tronconi MC; IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy., De Vincenzo F; IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in oncology [Front Oncol] 2023 Jul 31; Vol. 13, pp. 1205720. Date of Electronic Publication: 2023 Jul 31 (Print Publication: 2023). |
| DOI: | 10.3389/fonc.2023.1205720 |
| Abstrakt: | The use of immune checkpoint inhibitors (ICIs) for treating several types of cancer is increasing, but they may be associated with immune-related adverse events (irAEs). Pancreatitis is a rare irAE, mostly responsive to steroid treatment. There are no published data on the management of steroid-refractory ICI-induced pancreatitis. Rituximab has shown efficacy in the setting of relapsing non-ICI-induced autoimmune pancreatitis. However, its use has not been tested for treating immunotherapy-related pancreatitis. Here, we present the case of a patient with steroid-refractory immune-related pancreatitis successfully treated with rituximab as a potential strategy for irAE management. Competing Interests: AS participated in the advisory boards and speaker’s bureau of Bristol–Myers–Squibb, Servier, Pfizer, Eisai, Bayer, Merck Sharp & Dohme, Takeda, Roche, Abb-Vie, Amgen, Celgene, Gilead, Servier, AstraZeneca, Pfizer, Lilly, Sandoz, and Novartis. AS received consultancy fees from Sanofi and Incyte. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Santoro, Masini, Cavina, Tronconi and De Vincenzo.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|